Cyclooxygenase-2 (COX-2) up-regulation is a prognostic marker for poor clinical outcome of upper tract urothelial cancer

Anticancer Research

Volumn 32, Issue 9, 2012, Pages 4111-4116

  Ke, Hung Lung ^a,b   Tu, Hung Pin ^b   Lin, Hui Hui ^a   Chai, Chee Yin ^a   Chang, Lin Li ^b,c   Li, Wei Ming ^a,b,d   Li, Ching Chia ^b,e   Lee, Yi Chen ^b,c   Yeh, Hsin Chih ^a,d   Wu, Wen Jeng ^a,b,f   Bau, Da Tian ^g,h  

^a KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b Department of Otorhinolaryngology Head and Neck Surgery   (Taiwan)

^c KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^d Pingtung Hospital   (Taiwan)

^e KAOHSIUNG MUNICIPAL TA TUNG HOSPITAL   (Taiwan)

^f KAOHSIUNG MUNICIPAL HSIAO KANG HOSPITAL   (Taiwan)

^g CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^h CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Cox 2 positivity; Cyclooxygenase 2; Immunohistochemistry; Upper tract urothelial carcinoma

Indexed keywords

CYCLOOXYGENASE 2;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER GROWTH; CANCER LOCALIZATION; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SPECIFIC SURVIVAL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECURRENCE FREE SURVIVAL; STROMA CELL; TRANSITIONAL CELL CARCINOMA; UPREGULATION;

AGED; CYCLOOXYGENASE 2; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KIDNEY NEOPLASMS; KIDNEY PELVIS; MALE; MIDDLE AGED; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION; URETERAL NEOPLASMS; URINARY BLADDER NEOPLASMS; UROLOGIC NEOPLASMS;

EID: 84866984912     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Williams CB and Mitchell JP: Carcinoma of the ureter - A review of 54 cases. Br J Urol 45: 377-387, 1973.
2. Jemal A, Siegel R, Xu J and Ward E: Cancer statistics, 2010. CA Cancer J Clin 60: 277-300, 2011.
3. Chou YH and Huang CH: Unusual clinical presentation of upper urothelial carcinoma in Taiwan. Cancer 85: 1342-1344, 1999.
4. Lin HH, Ke HL, Hsiao KH, Tsai CW, Wu WJ, Bau DT and Chang LL: CCND1 1722 polymorphism and potential relevance to upper tract urothelial cancer. Anticancer Res 31: 1043-1047, 2011.
5. Lin HH, Ke HL, Hsiao KH, Tsai CW, Wu WJ, Bau DT and Chang LL: Potential role of CCND1 G870A genotype as a predictor for urothelial carcinoma susceptibility and muscle-invasiveness in Taiwan. Chin J Physiol 54: 196-202, 2011.
6. Miyata Y, Kanda S, Nomata K, Eguchi J and Kanetake H: Expression of cyclooxygenase-2 and EP4 receptor in transitional cell carcinoma of the upper urinary tract. J Urol 173: 56-60, 2005.
7. Ke HL, Chang LL, Yang SF, Lin HH, Li CC, Wu DC and Wu WJ: Osteopontin overexpression predicts poor prognosis of upper urinary tract urothelial carcinoma. Urol Oncol 29: 703-709, 2011.
8. Ke HL, Wei YC, Yang SF, Li CC, Wu DC, Huang CH and Wu WJ: Overexpression of hypoxia-inducible factor-1alpha predicts an unfavorable outcome in urothelial carcinoma of the upper urinary tract. Int J Urol 15: 200-205, 2008.
9. Yeh HC, Huang CH, Yang SF, Li CC, Chang LL, Lin HH, Ke HL, Wei YC and Wu WJ: Nuclear factor-kappaB activation predicts an unfavourable outcome in human upper urinary tract urothelial carcinoma. BJU Int 106: 1223-1229, 2011.
10. Suh O, Mettlin C and Petrelli NJ: Aspirin use, cancer, and polyps of the large bowel. Cancer 72: 1171-1177, 1993.
11. Trifan OC and Hla T: Cyclooxygenase-2 modulates cellular growth and promotes tumorigenesis. J Cell Mol Med 7: 207-222, 2003.
12. Wu HC, Chang CH, Ke HL, Chang WS, Cheng HN, Lin HH, Wu CY, Tsai CW, Tsai RY, Lo WC and Bau DT: Association of cyclooxygenase 2 polymorphic genotypes with prostate cancer in Ttaiwan. Anticancer Res 31: 221-225, 2011.
13. Wang CH, Wu KH, Yang YL, Peng CT, Wang RF, Tsai CW, Tsai RY, Lin DT, Tsai FJ and Bau DT: Association study of cyclooxygenase 2 single nucleotide polymorphisms and childhood acute lymphoblastic leukemia in Taiwan. Anticancer Res 30: 3649-3653, 2011.
14. Chang WS, Yang MD, Tsai CW, Cheng LH, Jeng LB, Lo WC, Lin CH, Huang CY and Bau DT: Association of cyclooxygenase 2 single-nucleotide polymorphisms and hepatocellular carcinoma in Taiwan. Chin J Physiol 55: 1-7, 2011.
15. Shiff SJ and Rigas B: Nonsteroidal anti-inflammatory drugs and colorectal cancer: evolving concepts of their chemopreventive actions. Gastroenterology 113: 1992-1998, 1997.
16. Subbaramaiah K, Zakim D, Weksler BB and Dannenberg AJ: Inhibition of cyclooxygenase: A novel approach to cancer prevention. Proc Soc Exp Biol Med 216: 201-210, 1997.
17. Cao Y and Prescott SM: Many actions of cyclooxygenase-2 in cellular dynamics and in cancer. J Cell Physiol 190: 279-286, 2002.
18. Mohammed SI, Knapp DW, Bostwick DG, Foster RS, Khan KN, Masferrer JL, Woerner BM, Snyder PW and Koki AT: Expression of cyclooxygenase-2 (COX-2) in human invasive transitional cell carcinoma (TCC) of the urinary bladder. Cancer Res 59: 5647-5650, 1999.
19. Shirahama T, Arima J, Akiba S and Sakakura C: Relation between cyclooxygenase-2 expression and tumor invasiveness and patient survival in transitional cell carcinoma of the urinary bladder. Cancer 92: 188-193, 2001.
20. Epstein JI, Amin MB, Reuter VR and Mostofi FK: The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee. Am J Surg Pathol 22: 1435-1448, 1998.
21. Greene FL, Page DL, Fleming ID, Fritz A, Balch CM, Haller DG: AJCC Cancer Staging Manual (6th ed). New York, Springer-Verlag, 2002.
22. Novara G, De Marco V, Gottardo F, Dalpiaz O, Bouygues V, Galfano A, Martignoni G, Patard JJ, Artibani W and Ficarra V: Independent predictors of cancer-specific survival in transitional cell carcinoma of the upper urinary tract: Multi-institutional dataset from three European centers. Cancer 110: 1715-1722, 2007.
23. Jeldres C, Sun M, Lughezzani G, Isbarn H, Shariat SF, Widmer H, Graefen M, Montorsi F, Perrotte P and Karakiewicz PI: Highly predictive survival nomogram after upper urinary tract urothelial carcinoma. Cancer 116: 3774-3784, 2011.
24. Shariat SF, Godoy G, Lotan Y, Droller M, Karakiewicz PI, Raman JD, Isbarn H, Weizer A, Remzi M, Roscigno M, Kikuchi E, Bolenz C, Bensalah K, Koppie TM, Kassouf W, Wheat JC, Zigeuner R, Langner C, Wood CG and Margulis V: Advanced patient age is associated with inferior cancer-specific survival after radical nephroureterectomy. BJU Int 105: 1672-1677, 2011.
25. Remzi M, Haitel A, Margulis V, Karakiewicz P, Montorsi F, Kikuchi E, Zigeuner R, Weizer A, Bolenz C, Bensalah K, Suardi N, Raman JD, Lotan Y, Waldert M, Ng CK, Fernandez M, Koppie TM, Strobel P, Kabbani W, Murai M, Langner C, Roscigno M, Wheat J, Guo CC, Wood CG and Shariat SF: Tumour architecture is an independent predictor of outcomes after nephroureterectomy: A multi-institutional analysis of 1363 patients. BJU Int 103: 307-311, 2009.
26. Lai MN, Wang SM, Chen PC, Chen YY and Wang JD: Population-based case-control study of Chinese herbal products containing aristolochic acid and urinary tract cancer risk. J Natl Cancer Inst 102: 179-186, 2011.
27. Hoellen F, Kelling K, Dittmer C, Diedrich K, Friedrich M and Thill M: Impact of cyclooxygenase-2 in breast cancer. Anticancer Res 31: 4359-4367, 2011.
28. Thiel G: How to fashion earplugs using cotton wool and petroleum jelly. Clin Otolaryngol 30: 378, 2005.
29. Moreira L and Castells A: Cyclooxygenase as a target for colorectal cancer chemoprevention. Curr Drug Targets 12: 1888-1894, 2011.
30. Mao JT, Cui X, Reckamp K, Liu M, Krysan K, Dalwadi H, Sharma S, Hazra S, Strieter R, Gardner B and Dubinett SM: Chemoprevention strategies with cyclooxygenase-2 inhibitors for lung cancer. Clin Lung Cancer 7: 30-39, 2005.
31. Bhoopathi P, Chetty C, Gujrati M, Dinh DH, Rao JS and Lakka SS: The role of MMP-9 in the anti-angiogenic effect of secreted protein acidic and rich in cysteine. Br J Cancer 102: 530-540, 2011.
32. Greenhough A, Smartt HJ, Moore AE, Roberts HR, Williams AC, Paraskeva C and Kaidi A: The COX-2/PGE 2 pathway: Key roles in the hallmarks of cancer and adaptation to the tumour microenvironment. Carcinogenesis 30: 377-386, 2009.
33. Sonoshita M, Takaku K, Oshima M, Sugihara K and Taketo MM: Cyclooxygenase-2 expression in fibroblasts and endothelial cells of intestinal polyps. Cancer Res 62: 6846-6849, 2002.
34. Sato N, Maehara N and Goggins M: Gene expression profiling of tumor-stromal interactions between pancreatic cancer cells and stromal fibroblasts. Cancer Res 64: 6950-6956, 2004.
35. Vandoros GP, Konstantinopoulos PA, Sotiropoulou-Bonikou G, Kominea A, Papachristou GI, Karamouzis MV, Gkermpesi M, Varakis I and Papavassiliou AG: PPAR-γ is expressed and NF-κB pathway is activated and correlates positively with COX-2 expression in stromal myofibroblasts surrounding colon adenocarcinomas. J Cancer Res Clin Oncol 132: 76-84, 2006.
36. Blot E, Chen W, Vasse M, Paysant J, Denoyelle C, Pille JY, Vincent L, Vannier JP, Soria J and Soria C: Cooperation between monocytes and breast cancer cells promotes factors involved in cancer aggressiveness. Br J Cancer 88: 1207-1212, 2003.
37. Chung LW, Baseman A, Assikis V and Zhau HE: Molecular insights into prostate cancer progression: the missing link of tumor microenvironment. J Urol 173: 10-20, 2005.
38. Sheehan KM, Sheahan K, O'Donoghue DP, MacSweeney F, Conroy RM, Fitzgerald DJ and Murray FE: The relationship between cyclooxygenase-2 expression and colorectal cancer. JAMA 282: 1254-1257, 1999.
39. Mrena J, Wiksten JP, Kokkola A, Nordling S, Ristimaki A and Haglund C: COX-2 is associated with proliferation and apoptosis markers and serves as an independent prognostic factor in gastric cancer. Tumour Biol 31: 1-7, 2010.